Data / Drug companies / I3 Pharmaceuticals, LLC
I3 Pharmaceuticals, LLC: 19 products in the FDA NDC directory, labeler code 72319
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
I3 Pharmaceuticals, LLC (labeler code 72319) lists 19 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 19 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 7, 2026.
The request: Watch I3 Pharmaceuticals, LLC (FDA labeler code 72319): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 72319
- Products in commercial distribution
- 19
- Packages
- 28
- Finished drugs by generic name
- 12
- Prescription products
- 19
- Over the counter products
- 0
- Flagged as original packager
- 19 of 19 products that carry the flag
- Started marketing in the last 12 months
- 6
- Earliest marketing start
- April 30, 2020
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 19 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 19 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Everolimus | 4 | 15 |
| Methscopolamine bromide | 2 | 5 |
| Maraviroc | 2 | 9 |
| Gaunfacine | 2 | 3 |
| Ranolazine | 2 | 30 |
| Posaconazole | 1 | 29 |
| Ramelteon | 1 | 29 |
| Selegiline hydrochloride | 1 | 12 |
| Isosorbide dinitrate and hydralazine hydrochloride | 1 | 3 |
| Clindamycin phosphate topical | 1 | 2 |
| Rifabutin | 1 | 5 |
| Tranexamic acid | 1 | 39 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 10 | 52.6% |
| Tablet, film coated | 4 | 21.1% |
| Tablet, film coated, extended release | 2 | 10.5% |
| Tablet, delayed release | 1 | 5.3% |
| Solution | 1 | 5.3% |
| Capsule | 1 | 5.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Everolimus | 72319-017 | Tablet | Generic drugs (ANDA) | August 7, 2026 |
| Everolimus | 72319-016 | Tablet | Generic drugs (ANDA) | August 7, 2026 |
| Everolimus | 72319-015 | Tablet | Generic drugs (ANDA) | August 7, 2026 |
| Everolimus | 72319-003 | Tablet | Generic drugs (ANDA) | August 7, 2026 |
| Tranexamic Acid | 72319-028 | Tablet | Generic drugs (ANDA) | June 30, 2026 |
| Rifabutin | 72319-010 | Capsule | Generic drugs (ANDA) | April 16, 2026 |
| Clindamycin phosphate | 72319-696 | Solution | Generic drugs (ANDA) | June 16, 2025 |
| Methscopolamine bromide | 72319-030 | Tablet | Generic drugs (ANDA) | December 18, 2024 |
| Methscopolamine bromide | 72319-029 | Tablet | Generic drugs (ANDA) | December 18, 2024 |
| Isosorbide dinitrate and hydralazine hydrochloride | 72319-012 | Tablet, film coated | Generic drugs (ANDA) | February 7, 2024 |
| Maraviroc | 72319-025 | Tablet, film coated | Generic drugs (ANDA) | September 15, 2023 |
| Maraviroc | 72319-024 | Tablet, film coated | Generic drugs (ANDA) | September 15, 2023 |
| Posaconazole | 72319-023 | Tablet, delayed release | Generic drugs (ANDA) | September 15, 2023 |
| Guanfacine | 72319-019 | Tablet | Generic drugs (ANDA) | October 31, 2022 |
| Guanfacine | 72319-018 | Tablet | Generic drugs (ANDA) | October 31, 2022 |
| Ranolazine | 72319-022 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 15, 2022 |
| Ranolazine | 72319-021 | Tablet, film coated, extended release | Generic drugs (ANDA) | June 15, 2022 |
| Selegiline Hydrochloride | 72319-006 | Tablet | Generic drugs (ANDA) | December 15, 2021 |
| Ramelteon | 72319-005 | Tablet, film coated | Generic drugs (ANDA) | April 30, 2020 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.